Literature DB >> 17020756

Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction.

Claudia Korandji1, Marianne Zeller, Jean-Claude Guilland, Catherine Vergely, Pierre Sicard, Laurence Duvillard, Philippe Gambert, Daniel Moreau, Yves Cottin, Luc Rochette.   

Abstract

OBJECTIVES: We sought to investigate the association between increased levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and total plasma homocysteinemia (tHcy) in patients with acute myocardial infarction (AMI). DESIGN AND METHODS: In 138 patients hospitalized for AMI <24 h on admission, serum levels of ADMA, its symmetric stereoisomer (SDMA) and tHcy were measured.
RESULTS: ADMA was positively associated with SDMA (p<0.001) and tHcy (p=0.03) but not with estimated glomerular filtration rates (eGFR, p=0.96), while tHcy strongly correlated with eGFR (p=0.002) and SDMA (p<0.001). By multiple linear regression, SDMA but not ADMA was independently associated with tHcy (p=0.005).
CONCLUSION: Our findings suggest that, in AMI patients, hyperhomocysteinemia is indirectly related to ADMA levels via renal function. Moreover, ADMA level was independent of traditional cardiovascular risk factors in AMI patients. Interestingly, our findings suggest that SDMA could be a good risk indicator for cardiovascular disease in AMI patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020756     DOI: 10.1016/j.clinbiochem.2006.08.004

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

1.  Coronary artery disease: Can aminothiols be distinguished from reactive oxygen species?

Authors:  Luc Rochette; Catherine Vergely
Journal:  Nat Rev Cardiol       Date:  2016-02-11       Impact factor: 32.419

2.  Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia.

Authors:  Roman N Rodionov; Hayan Dayoub; Cynthia M Lynch; Katina M Wilson; Jeff W Stevens; Daryl J Murry; Masumi Kimoto; Erland Arning; Teodoro Bottiglieri; John P Cooke; Gary L Baumbach; Frank M Faraci; Steven R Lentz
Journal:  Circ Res       Date:  2009-12-17       Impact factor: 17.367

3.  Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.

Authors:  Sanjana Dayal; Roman N Rodionov; Erland Arning; Teodoro Bottiglieri; Masumi Kimoto; Daryl J Murry; John P Cooke; Frank M Faraci; Steven R Lentz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

4.  Increased Symmetric Dimethylarginine Level Is Associated with Worse Hospital Outcomes through Altered Left Ventricular Ejection Fraction in Patients with Acute Myocardial Infarction.

Authors:  Julie Lorin; Jean-Claude Guilland; Karim Stamboul; Charles Guenancia; Yves Cottin; Luc Rochette; Catherine Vergely; Marianne Zeller
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

Review 5.  Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis.

Authors:  Manuela Di Franco; Bruno Lucchino; Fabrizio Conti; Guido Valesini; Francesca Romana Spinelli
Journal:  Mediators Inflamm       Date:  2018-01-18       Impact factor: 4.711

6.  Evaluation of serum Asymmetric Dimethyl Arginine concentrations in coronary artery disease patients without traditional cardiovascular risk factors.

Authors:  Majid Ghayour-Mobarhan; Nayyereh Ayati; Amirhossein Sahebkar; Mohsen Moohebati; Narjes Ayati; Sepideh Elyasi; Amir Houshang Mohammadpour
Journal:  Acta Biomed       Date:  2018-06-07

7.  Transsulfuration pathway thiols and methylated arginines: the Hunter Community Study.

Authors:  Arduino A Mangoni; Angelo Zinellu; Ciriaco Carru; John R Attia; Mark McEvoy
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

8.  Demethylation treatment restores erectile function in a rat model of hyperhomocysteinemia.

Authors:  Zheng Zhang; Lei-Lei Zhu; He-Song Jiang; Hai Chen; Yun Chen; Yu-Tian Dai
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.